Li Liu, Yang Li, Yang Feng, Zhao Xin-Lan, Xue Shengjiang, Gong Fang-Hua
No.2 Department of Endocrinology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410002, People's Republic of China.
No.2 Department of Pharmacy, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, 410002, People's Republic of China.
J Inflamm Res. 2021 May 17;14:1959-1971. doi: 10.2147/JIR.S302934. eCollection 2021.
extract 50 (GBE50) has a variety of pharmacological functions such as anti-inflammatory, antioxidant and maintenance of glucose and lipid metabolism homeostasis. However, the therapeutic effects and mechanisms of GBE50 on non-alcoholic fatty liver disease (NAFLD) remain unknown. Therefore, in this study, we evaluated the therapeutic effects of GBE50 in NAFLD by using a high-fat diet (HFD) mice model.
C57BL/6J mice were fed a HFD diet for 15 weeks and were given respectively 25, 50, and 100 mg/kg GBE50 daily by gavage from 3 to 15 weeks. After the administration, blood samples and liver tissues were collected for biochemical detection, histological measurement, immunohistochemistry and Western blot, respectively.
We found that GBE50 treatment could ameliorate insulin resistance (IR), glucose intolerance, lipid accumulation, hepatic steatosis and liver injury in HFD-fed mice. Further mechanism exploration discovered that the hepatoprotective effects of GBE50 on NAFLD may be related to the strengthening of IRS-1 signal activation and the weakening of NF-κB, Akt and endoplasmic reticulum stress signals activation.
GBE50 is a potentially powerful therapeutic agent for the treatment of NAFLD.
银杏叶提取物50（GBE50）具有多种药理功能，如抗炎、抗氧化以及维持糖脂代谢稳态。然而，GBE50对非酒精性脂肪性肝病（NAFLD）的治疗作用及机制仍不清楚。因此，在本研究中，我们通过高脂饮食（HFD）小鼠模型评估了GBE50对NAFLD的治疗作用。
将C57BL/6J小鼠喂食HFD饮食15周，并在第3至15周分别通过灌胃给予25、50和100 mg/kg GBE50。给药后，分别采集血液样本和肝脏组织进行生化检测、组织学测量、免疫组织化学和蛋白质免疫印迹分析。
我们发现GBE50治疗可改善HFD喂养小鼠的胰岛素抵抗（IR）、葡萄糖不耐受、脂质蓄积、肝脏脂肪变性和肝损伤。进一步的机制探索发现，GBE50对NAFLD的肝脏保护作用可能与增强IRS-1信号激活以及减弱NF-κB、Akt和内质网应激信号激活有关。
GBE50是一种治疗NAFLD的潜在有效治疗剂。
